The 23 most recent market catalysts affecting $ARWR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Goldman Sachs analyst Andrea Newkirk has reinstated coverage on Arrowhead Pharma (ARWR) with a 'Neutral' rating and a $74 price target. This event is significant as it provides an …
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 85
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals reported highly positive interim Phase 1/2a clinical data for ARO-DIMER-PA, its novel RNAi therapeutic. The drug achieved deep and durable silencing of PC…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
Arrowhead Pharmaceuticals Says Phase 1/2a Interim Single-Dose Data For ARO-DIMER-PA Showed Mean Maximal Reductions Of 54% In Bad Cholesterol, 73% In Triglycerides; No Drug-Related Serious Adverse Events
This headline represents a significant positive catalyst for Arrowhead Pharmaceuticals (ARWR). The impressive reductions in LDL-C and triglycerides, coupled with a clean safety pro…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 65
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108
Citigroup's initiation of coverage on Arrowhead Pharma (ARWR) with a 'Buy' rating and a $108 price target is a positive development for the company. Analyst coverage, especially fr…
Aug 31, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
RBC Capital analyst Luca Issi reiterated an 'Outperform' rating and a $100 price target for Arrowhead Pharma (ARWR). This action signals continued confidence from a prominent analy…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Arrowhead Pharmaceuticals reported highly positive Phase 3 results for its drug plozasiran, demonstrating deep and durable reductions in triglycerides and a significant reduction i…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress
Arrowhead Pharmaceuticals (ARWR) has announced its intention to present new data on Plozasiran, a drug for severe hypertriglyceridemia, at the European Society of Cardiology Congre…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 75
Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome
Arrowhead Pharmaceuticals has achieved a significant milestone with REDEMPLO's authorization and reimbursement in Germany, a major European market. This allows the drug to be presc…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120
HC Wainwright & Co. analyst Patrick R. Trucchio maintained a 'Buy' rating on Arrowhead Pharma (ARWR) and raised the price target from $115 to $120. This action signals continued bu…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate
Arrowhead Pharma's Q3 earnings report presents a mixed picture for investors. The substantial beat in sales, driven by a 171% year-over-year increase, suggests strong product deman…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pediatric Disease Priority Review Voucher For Its Upcoming SNDA Submission For Plozasiran, Anticipated Before The End Of 2026
Arrowhead Pharmaceuticals (ARWR) has announced the acquisition of a Priority Review Voucher (PRV) for its upcoming SNDA submission for plozasiran, targeting severe hypertriglycerid…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123
This filing indicates that B. Riley Securities analyst Madison El-Saadi has maintained a 'Buy' rating on Arrowhead Pharma (ARWR) and raised the price target from $101 to $123. This…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 65
Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals has completed patient enrollment in its global Phase 3 YOSEMITE clinical trial for zodasiran, targeting homozygous familial hypercholesterolemia (HoFH). T…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115
HC Wainwright & Co. analyst Patrick R. Trucchio maintained a 'Buy' rating on Arrowhead Pharma (ARWR) and raised the price target from $100 to $115. This action signals increased an…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 65
Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120
Morgan Stanley analyst Michael Ulz has maintained an 'Overweight' rating on Arrowhead Pharma (ARWR) and raised the price target from $100 to $120. This action by a prominent invest…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126
Piper Sandler analyst Edward Tenthoff reiterated an 'Overweight' rating on Arrowhead Pharma (ARWR) and raised the price target from $110 to $126. This action signals continued conf…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 55
Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115
Chardan Capital's analyst Keay Nakae has maintained a 'Buy' rating for Arrowhead Pharma and raised the price target from $90 to $115. This action signals increased confidence in th…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 92
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat
Arrowhead Pharmaceuticals (ARWR) released highly positive Phase 3 trial results for plozasiran, showing substantial efficacy in reducing triglycerides and acute pancreatitis in sev…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 85
Arrowhead Pharmaceuticals shares are trading higher after the company announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies met their primary and secondary endpoints.
The successful completion of Phase 3 clinical trials for SHASTA-3 and SHASTA-4 is a major corporate catalyst for Arrowhead Pharmaceuticals. Meeting both primary and secondary endpo…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 85
Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline
Arrowhead Pharmaceuticals reported highly positive topline results for its plozasiran drug in treating severe hypertriglyceridemia (sHTG). The drug demonstrated deep, durable, and …
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
Arrowhead Pharmaceuticals shares are trading higher after JP Morgan raised its price target on the stock from $88 to $95.
The upgrade by a major investment bank like JP Morgan from $88 to $95 for Arrowhead Pharmaceuticals (ARWR) is a significant positive catalyst. It indicates a more optimistic outloo…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 65
This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
The filing announces new analyst coverage for five companies, providing fresh perspectives and price targets. This is significant for investors as analyst initiations often lead to…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 65
Stifel Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $98
Stifel analyst James Condulis initiated coverage on Arrowhead Pharma (ARWR) with a 'Buy' rating and a $98 price target. This is a positive development for ARWR as new analyst cover…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.